These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29190391)

  • 21. Selection of therapeutic treatment with alternating chemoradiotherapy for larynx preservation in laryngeal carcinoma patients.
    Ijichi K; Hanai N; Kawakita D; Ozawa T; Suzuki H; Hirakawa H; Kodaira T; Murakami S; Hasegawa Y
    Jpn J Clin Oncol; 2014 Nov; 44(11):1063-9. PubMed ID: 25187666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience.
    Nguyen-Tan PF; Le QT; Quivey JM; Singer M; Terris DJ; Goffinet DR; Fu KK
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1172-80. PubMed ID: 11483326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
    Posner MR; Norris CM; Wirth LJ; Shin DM; Cullen KJ; Winquist EW; Blajman CR; Mickiewicz EA; Frenette GP; Plinar LF; Cohen RB; Steinbrenner LM; Freue JM; Gorbunova VA; Tjulandin SA; Raez LE; Adkins DR; Tishler RB; Roessner MR; Haddad RI;
    Ann Oncol; 2009 May; 20(5):921-7. PubMed ID: 19179556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: A National Cancer Data Base analysis.
    Stokes WA; Jones BL; Bhatia S; Oweida AJ; Bowles DW; Raben D; Goddard JA; McDermott JD; Karam SD
    Cancer; 2017 Feb; 123(4):600-608. PubMed ID: 27727461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Organ sparing treatment modalities - which type of treatment for which carcinoma?].
    Kornek GV; Selzer E
    Wien Med Wochenschr; 2008; 158(9-10):264-9. PubMed ID: 18560952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes of 849 laryngeal cancers treated in the past 40 years: are we succeeding?
    Nakayama M; Okamoto M; Hayakawa K; Miyamoto S; Ishiyama H; Komori S; Okamoto T; Seino Y; Kano K; Soda I; Sekiguchi A; Kawakami S
    Jpn J Clin Oncol; 2014 Jan; 44(1):57-64. PubMed ID: 24174633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Organ preservation for advanced larynx cancer: A review of chemotherapy and radiation combination strategies.
    Bonomi MR; Blakaj A; Blakaj D
    Oral Oncol; 2018 Nov; 86():301-306. PubMed ID: 30409316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.
    Haddad RI; Posner M; Hitt R; Cohen EEW; Schulten J; Lefebvre JL; Vermorken JB
    Ann Oncol; 2018 May; 29(5):1130-1140. PubMed ID: 29635316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment results and prognostic factors for advanced squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy.
    Taguchi T; Nishimura G; Takahashi M; Komatsu M; Sano D; Sakuma N; Arai Y; Yamashita Y; Shiono O; Hirama M; Sakuma Y; Ishitoya J; Hata M; Ogino I; Oridate N
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):837-43. PubMed ID: 23959463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laryngeal cancer: United Kingdom National Multidisciplinary guidelines.
    Jones TM; De M; Foran B; Harrington K; Mortimore S
    J Laryngol Otol; 2016 May; 130(S2):S75-S82. PubMed ID: 27841116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
    Forastiere AA; Zhang Q; Weber RS; Maor MH; Goepfert H; Pajak TF; Morrison W; Glisson B; Trotti A; Ridge JA; Thorstad W; Wagner H; Ensley JF; Cooper JS
    J Clin Oncol; 2013 Mar; 31(7):845-52. PubMed ID: 23182993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approaches to preserve larynx function in locally advanced laryngeal and hypopharyngeal cancer.
    Rudat V; Pfreundner L; Hoppe F; Dietz A
    Onkologie; 2004 Aug; 27(4):368-75. PubMed ID: 15347892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials.
    Sanabria A; Chaves ALF; Kowalski LP; Wolf GT; Saba NF; Forastiere AA; Beitler JJ; Nibu KI; Bradford CR; Suárez C; Rodrigo JP; Strojan P; Rinaldo A; de Bree R; Haigentz M; Takes RP; Ferlito A
    Auris Nasus Larynx; 2017 Feb; 44(1):18-25. PubMed ID: 27397024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional organ preservation in locally advanced laryngeal squamous cell carcinoma: is there a role for induction chemotherapy?
    Loo SW; Geropantas K; Roques TW
    Clin Oncol (R Coll Radiol); 2013 May; 25(5):298-307. PubMed ID: 23290343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Candidates for larynx preservation: the next step?
    Lefebvre JL
    Oncologist; 2010; 15 Suppl 3():30-2. PubMed ID: 21036887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
    Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between response to induction chemotherapy and disease control in patients with advanced laryngeal carcinoma included in an organ preservation protocol.
    León X; Valero C; Rovira C; Rodriguez C; López M; García-Lorenzo J; Quer M
    Eur Arch Otorhinolaryngol; 2017 Jun; 274(6):2581-2587. PubMed ID: 28349204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predisposing factors for larynx preservation strategies with non-surgical multimodality treatment for locally advanced (T3-4) larynx, hypopharynx and cervical esophageal disease.
    Suzuki G; Yamazaki H; Ogo E; Abe T; Eto H; Muraki K; Hattori C; Umeno H; Tanaka N; Tanaka T; Nakamura S; Yoshida K
    Anticancer Res; 2014 Sep; 34(9):5205-10. PubMed ID: 25202116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparative analysis of clinical efficacies between induction chemotherapy and surgery combined with radiotherapy or concurrent chemoradiotherapy in advanced hypopharyngeal carcinoma].
    Li ZD; Lu T
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Dec; 53(12):918-924. PubMed ID: 30585004
    [No Abstract]   [Full Text] [Related]  

  • 40. Modifications in the treatment of advanced laryngeal cancer throughout the last 30 years.
    García Lorenzo J; Montoro Martínez V; Rigo Quera A; Codina Aroca A; López Vilas M; Quer Agustí M; León Vintró X
    Eur Arch Otorhinolaryngol; 2017 Sep; 274(9):3449-3455. PubMed ID: 28625009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.